ZYME
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Zymeworks received FDA Fast Track designation for ZW191 targeting FRαMar 30, 2026
- Zymeworks announced positive HERIZON-GEA-01 Phase 3 results supporting Ziihera® (zanidatamab-hrii) as HER2-targeted agent of choice and new standard of care in first-line HER2-positive advanced gastroesophageal adenocarcinomaNov 17, 2025
- Zymeworks discontinues clinical development of mesothelin-directed T cell engager ZW171 following Phase 1 dose escalation reviewSep 2, 2025
- Zymeworks secures NMPA approval of Zanidatamab in China for adults with previously treated, unresectable, or metastatic HER2-high biliary tract cancerMay 30, 2025